Adachi J D, Bensen W G, Hodsman A B
Department of Medicine, St Joseph's Hospital, McMaster University, Hamilton, Ontario, Canada.
Semin Arthritis Rheum. 1993 Jun;22(6):375-84. doi: 10.1016/s0049-0172(05)80029-0.
Corticosteroid-induced osteoporosis is a major problem faced by rheumatologists, with up to 50% of patients at increased risk for vertebral fractures. Our current understanding of the pathophysiology of corticosteroid-induced osteoporosis suggests two basic problems: a reduction in bone formation and an increase in bone resorption leading to an overall reduction in bone mass. Adequate calcium and vitamin D intake, calcitonin, hormone-replacement therapy, and thiazide diuretics are of benefit in preventing corticosteroid-induced bone loss. Other therapies such as the bisphosphonates, fluoride, and anabolic steroids should be considered when fractures occur or ongoing bone loss is evident. A review of the literature outlining the pathophysiology, clinical features, assessment, and treatment is presented.
糖皮质激素诱导的骨质疏松症是风湿病学家面临的一个主要问题,高达50%的患者发生椎体骨折的风险增加。我们目前对糖皮质激素诱导的骨质疏松症病理生理学的理解表明存在两个基本问题:骨形成减少和骨吸收增加,导致骨量总体减少。充足的钙和维生素D摄入、降钙素、激素替代疗法和噻嗪类利尿剂对预防糖皮质激素诱导的骨质流失有益。当发生骨折或明显存在持续骨质流失时,应考虑使用其他疗法,如双膦酸盐、氟化物和合成代谢类固醇。本文对概述其病理生理学、临床特征、评估和治疗的文献进行了综述。